OQROGet OQRO Pro
Fund moves

Oric Pharmaceuticals (ORIC)Paradigm Biocapital Advisors LP opened a new position $19.6M

Paradigm Biocapital Advisors LP opened a new position in Oric Pharmaceuticals, per its Q4 2025 13F.

2.4M
Shares reported
0.50%
Disclosed portfolio weight
$19.6M
Reported value
Holdings as of
Dec 31, 2025
Filed
Feb 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

    What came next

    1. Feb 23, 2026Company filing · Form 8-K · ResultsReported its results
    2. May 4, 2026Company filing · Form 8-K · ResultsReported its results
    View the official recordSEC Form 13F-HR

    How to read SEC Form 13F-HR

    Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

    Full guide: What is an SEC Form 13F?

    What else is on file for Oric Pharmaceuticals

    For Oric Pharmaceuticals, OQRO holds 5 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

    These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ORIC page.

    How this filing works

    Other disclosures at Oric Pharmaceuticals

    Everything OQRO holds on this company is on its ORIC page.

    This is one filing. OQRO holds the rest

    Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

    Unlock OQRO ProAlready have an account? Log in

    OQRO Pro is a paid subscription. You see the price before you pay

    OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data